Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

mobidiag antibiotic resistance diagnostic

News and Trends 15 May 2019

€25M European Loan to Fund Diagnostics Tackling Antibiotic Resistance

The Finnish biotech Mobidiag has received a loan of €25M from the European Investment Bank to commercialize diagnostic technology aimed at reducing antibiotic resistance. When patients get a bacterial infection, clinicians have to wait several days for traditional diagnosis techniques to tell them what kind of bacteria is causing the infection. While they wait, the […]

May 15, 2019 - 2 minutesmins - By Jonathan Smith

human microbiome research

In Depth 15 May 2019

The Missing Piece in the Microbiome Field

Over the last decade, the biotech industry has built a lot of hype around the emerging field of microbiome research. Its potential to treat all sorts of diseases has captured the imagination of scientists and the number of early-stage studies is growing massively day by day. These studies have found correlation between the human microbiome […]

May 15, 2019 - 7 minutesmins - By Clara Rodríguez Fernández

HEADER Inova metamorworks

Sponsored 15 May 2019

6 Tips on How to Choose the Best Software Solution for Your Biopharma Partnering

Biotechnology is booming. Everyone working in the life science industry knows it and the numbers say so too. By 2025, for instance, the global biotech market is estimated to reach $727Bn. But this fast-paced environment also comes with its pitfalls. The great increase in competition leaves many companies struggling to find the necessary funds, the […]

May 15, 2019 - 9 minutesmins - By External Contributor

celixir rnai silencing cancer colon breast

News and Trends 14 May 2019

RNAi Therapy Smashes Solid Tumors in Preclinical Tests

Developed by the UK biotech Celixir, a therapy based on silencing genes with RNA molecules in a process called RNAi has shrunk tumors by 50% in culture. Although there are lots of innovative cancer treatments in the market, such as CAR T-cell therapy for blood cancer, solid tumors remain difficult to tackle. For this reason, […]

May 14, 2019 - 2 minutesmins - By Jonathan Smith

EryDel Red Blood Cells

News and Trends 14 May 2019

First Potential Gene Therapy for Hemophilia B Restores Blood Clotting in Phase II

A gene therapy developed by the Dutch biotech uniQure increased the activity of a blood clotting protein enough to stop bleeds in patients with the blood disorder hemophilia B. Hemophilia B is a rare genetic condition in which patients have a mutation in the blood clotting protein factor IX (FIX), reducing its activity below 6% […]

May 14, 2019 - 3 minutesmins - By Jonathan Smith

cancer immunotherapy philogen melanoma

News and Trends 13 May 2019

‘Guided Missile’ Cancer Immunotherapy Boosted by €62M Funding

The Swiss-Italian biotech company Philogen has raised a private round of €62M to fund the phase III development of cancer immunotherapies that deliver immune cell-stimulating molecules directly to the tumor site. The money will push Philogen’s two lead cancer programs, currently in phase III, to the market. The funds will also help to expand the […]

May 13, 2019 - 2 minutesmins - By Jonathan Smith

ADVERTISEMENT

biontech cancer vaccine mrna immunotherapy

Interview 13 May 2019

Putting DNA Repair on the Map

Niall Martin is on a mission to put DNA repair on the map. He has already gone pretty far along the way to doing this, as the leader of the team that developed the blockbuster cancer drug Lynparza. He is now seeking to repeat this early success at Artios, where he is CEO. Martin talked […]

May 13, 2019 - 8 minutesmins - By Helen Albert

treefrog therapeutics cell therapy parkinsons disease

News and Trends 13 May 2019

Cell Encapsulation Biotech Raises €7M to Target Cell Therapy Bottlenecks

The French company Treefrog Therapeutics has raised over €7M in Series A investment to develop its encapsulation technology to improve the production of stem cells for cell therapies. Part of the Series A money will help Treefrog to automate its stem cell production process by 2021. The round will also fund the development of a […]

May 13, 2019 - 3 minutesmins - By Jonathan Smith

pneumonia lungs polyphor antibiotic resistance

News and Trends 10 May 2019

Swiss Biotech Halts Pneumonia Antibiotic Trial After Patient Safety Scare

Polyphor has temporarily halted two phase III trials of an antibiotic treating pneumonia, after an unexpectedly high number of patients reported kidney problems in one of the trials. The phase III trial was testing the antibiotic murepavadin in 150 enrolled patients with hospital-acquired pneumonia, and who required mechanical breathing. The patients in the treatment group […]

May 10, 2019 - 3 minutesmins - By Jonathan Smith

polyprox cambridge cancer protac drug

Startup Scout 10 May 2019

This Biotech Destroys Cancer Proteins by Introducing Them to ‘Executioner’ Proteins

Nestled in the biotech hub of Cambridge, UK, is Polyprox. Less than a year old, this company is developing a new class of protein-based drugs that could treat cancer by degrading key proteins in the cancer cell. Mission: Develop drugs that destroy proteins in cancer cells by recruiting executioner proteins, called ligases. Polyprox develops protein […]

May 10, 2019 - 4 minutesmins - By Jonathan Smith

Peptomyc myc cancer drug

Interview 9 May 2019

A 20-Year Journey to Nail Down an Undruggable Cancer Target

The ultimate goal of cancer research is to bring to the market a drug that improves the treatment of patients lacking options. Laura Soucek, CEO of the startup Peptomyc, shares the story of her journey to take a cancer treatment against an until now undruggable target to the clinic. It all started when Soucek was […]

May 9, 2019 - 5 minutesmins - By Clara Rodríguez Fernández

achondroplasia pfizer therachon acquisition

More News! 9 May 2019

Pfizer Pays up to €700M to Acquire Swiss Biotech Restoring Bone Growth in Achondroplasia

Pharma giant Pfizer is acquiring the Swiss biotech Therachon, which is developing a protein drug to boost bone growth in the genetic condition achondroplasia. Pfizer will pay €303M ($340M) upfront, and up to €420M ($470M) dependent on Therachon reaching milestones in the development of its drug improving bone growth in achondroplasia. This genetic condition inhibits […]

May 9, 2019 - 2 minutesmins - By Jonathan Smith

ADVERTISEMENT